Immune Response mit Quartalszahlen...

Heute meine MEGA-Verlustposition mit Quartalszahlen...

Durchschnittserwartung der Analysten: -8 cents/share oder -31 cents für 2000
Geliefert: +1 cent/share....!!!
Cash steigt von 23 Mio.$ auf 29 Mio.

Bitte Nasdaq, laß das nicht einfach so vorrübergehen, auch wenns ein Biotech Research Laden ist und eigentlich schnuppe.

The Immune Response Corporation Announces First Quarter 2000 Financial Results

   CARLSBAD, Calif., May 11 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) today announced its financial results for the quarter ended
March 31, 2000.  The net income for the first quarter of 2000 was $421,000, or
$.01 per share, compared to a net loss of $1.3 million, or a loss of $.07 per
share, reported in the first quarter of 1999.
   Research related revenue for the quarter ended March 31, 2000 was
$3.3 million compared to $9.2 million for the same quarter in 1999.  The
decrease in research related revenue was primarily attributable to a
$5.0 million milestone payment from Agouron Pharmaceuticals, Inc. ("Agouron"),
a Warner-Lambert Company, paid in the first quarter of 1999.  In addition to
research related revenue, the Company received non-research revenue from
investment and other income of $3.3 million for the first quarter of 2000
versus $380,000 for the same period in 1999.  This other revenue was primarily
due to the sale of an equity security held for sale that was acquired through
the licensing of technology and from the sale of undeveloped property.
   Operating expenses decreased to $6.2 million for the quarter ended March
31, 2000 from $10.9 million in the first quarter of 1999.  The decrease in
operating expenses was primarily the result of the Company's workforce
reduction in June 1999, along with a decrease in clinical and regulatory
expenses.
   Cash, cash equivalents and short-term investments were $29.2 million at
March 31, 2000 compared with $23.1 million at the end of 1999.

Gruß
ein hoffender Drogo

Das das mit Remune klappt, dessen bin ich mir sicher. Aber erstaunlich finde ich wirklich, daß die vorher schon Gewinne machen. Wünsche Dir auch, daß der Kurs entsprechend reagiert.
Natürlich nicht ohne Eigennutz.

soreness and redness at the site of injection, muscle aches, fatigue, and
headache.

The primary objective of this 96 week, randomized, double-blind,
adjuvant-controlled study is to determine whether the addition of REMUNE to a
regimen of potent, suppressive antiretroviral therapy delays the time to
virologic relapse (defined as a predetermined level of HIV-1 RNA detected in the
plasma). The trial is expected to enroll a total of 472 people and will be open
to all Adult AIDS Clinical Trial Units and their subunits. The first scheduled
data analysis of the trial will be conducted at 48 weeks to assess differences
between control and REMUNE-treated groups in time to virological relapse.

werde mir sie jetzt irgendwann wieder holen

Nach dem erfolgreichen Abschluß der Tests in Thailand, dem extremen Kursverfall inzwischen! und einer Zeitspanne von ca. 6 Wochen seither -
werden nun die klinischen Tests auch in den USA gestartet.
Remune ist das erste Präparat gegen Aids, das in diese Testphase gelangt!!!

NIH to test Remune AIDS virus vaccine

   NEW YORK, May 11 (Reuters) - The U.S. National Institutes
of Health will begin a pivitol trial of the experimental Remune
vaccine for people infected with the AIDS virus, said Immune
Response Corp. , the vaccine's maker.
   In a statement on Wednesday, Immune Response said that in
the tests Remune will be added to standard combination drug
therapy for patients infected with the AIDS virus, HIV.
   Remune is a so-called therapeutic vaccine and is intended
to stimulate the immune system to destroy HIV-infected cells.
The study is aimed at determining whether Remune, when used in
combination with standard therapies, can suppress levels of HIV
in the blood longer than standard therapy taken alone.
   Carlsbad, Calif-based Immune Response said the trial is
expected to enroll 472 people. The first scheduled data
analysis of the trail will be conducted at 48 weeks to assess
differences betwen control and Remune-treated groups.
             ((New York Newsroom 212-859-1700))

steht......noch auf keinem Board zu finden! Go Kicky ;-)

wissen mit der meldung nichts anzufangen??

tschau woody

Berichterstattung dauert normalerweise etwas bzw. erst heute Abend auf CNN.
Auf den Boards ist noch nichts zu finden, und die sind normalerweise relativ schnell.

Die Entwicklung gibt mir recht...erst runter auf +3% jetzt +7%.....

 

ich habe immune auch im Depot und bin nach diesen guten Nachrichten sehr froh darüber.